PCM
ACHV icon

Prelude Capital Management’s Achieve Life Sciences ACHV Stock Holding History

Prelude Capital Management’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2
Closed -$42K – 1872
2014
Q1 		$42K Buy
+2
New +$49.1K 0.01% 1359

Other funds holding ACHV

SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Prelude Capital Management's ACHV Position: Q4 2023 in Review

Prelude Capital Management sold out of Achieve Life Sciences (ACHV) in Q4 2023, closing a stake of 25,429 shares — an estimated $109K sold.

Prelude Capital Management first reported a position in ACHV in Q2 2013 and held it in 18 quarters. The position peaked at $140K in Q2 2023. 30 funds tracked by Wall St. Rank hold ACHV as of Q4 2023.

  • Prelude Capital Management reported no remaining Achieve Life Sciences position as of Q4 2023 after selling out during the quarter.
  • Prelude Capital Management sold 25,429 Achieve Life Sciences shares in Q4 2023, an estimated $109K.
  • Prelude Capital Management first reported a position in Achieve Life Sciences in Q2 2013 and held it in 18 quarters.
  • Prelude Capital Management's Achieve Life Sciences position peaked at $140K in Q2 2023.
  • 30 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q4 2023.

Based on Prelude Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.